Bexlosteride
Chemical compound
- none
- In general: uncontrolled
- (4aR,10bR)-8-Chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
- 148905-78-6
N
- 166562
- 145762
Y
- 36X732P4P0
- ChEMBL24955
Y
- Interactive image
- CN1[C@@H]2CCc3cc(ccc3[C@H]2CCC1=O)Cl
InChI
- InChI=1S/C14H16ClNO/c1-16-13-6-2-9-8-10(15)3-4-11(9)12(13)5-7-14(16)17/h3-4,8,12-13H,2,5-7H2,1H3/t12-,13-/m1/s1
Y
- Key:WQBIOEFDDDEARX-CHWSQXEVSA-N
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Bexlosteride is a potent and noncompetitive inhibitor of the enzyme 5α-reductase related to finasteride and dutasteride.[1][2] It is selective for the type I isoform of the enzyme.[1] It advanced to Phase III clinical trials, but development was halted at that stage, and it was never marketed.[3][4]
See also
References
- ^ a b Chang C (2002). Androgens and androgen receptor : mechanisms, functions, and clinical application. Boston: Kluwer Academic Publishers. ISBN 1-4020-7188-4.
- ^ Lednicer D (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 978-0-470-19039-5.
- ^ "Drug Profile: Bexlosteride". Adis Insight.
- ^ Reaxys entry for bexlosteride: Reaxys Registry Number: 6635310
- v
- t
- e
Drugs used in benign prostatic hyperplasia (G04C)
- Pygeum africanum
- Saw palmetto extract